SOLA Biosciences Japan Secures 6 Billion Yen Grant to Advance ALS Gene Therapy

SOLA Biosciences Japan GK, a subsidiary of Boston-based SOLA Biosciences Inc., has received a grant of approximately 6 billion yen from the Japan Agency for Medical Research and Development (AMED) to advance its gene therapy program SOL-257 for amyotrophic lateral sclerosis (ALS).